Thank you for your interest in this Presentation Theatre supported by Sobi™ and Sanofi, entitled “Insights From Real World Practice to Support Haemophilia B Patients” at the XXX Congress of the International Society on Thrombosis and Haemostasis (ISTH) in London, United Kingdom on Tuesday, 12 July 2022.
During this Presentation Theatre, our faculty will discuss the unmet treatment needs of patients with haemophilia B and how these can be overcome to achieve the desired outcomes for the patient. The expert speakers will review patient cases and discuss their experiences in the treatment of patients with haemophilia B, reflecting on the available treatment options including extended half-life factor replacement therapies, such as Alprolix® (eftrenonacog alfa).
We hope that you find this Presentation Theatre engaging and conducive to stimulating discussions, and we look forward to you joining us.
Professor, BA, BMBCh, DM, FRCP, FRCPath
Consultant Haematologist
Imperial College
London, United Kingdom
12.15–12.25
Michael Laffan (Chair)
United Kingdom
12.25–12.55
Niamh O’Connell
Ireland
Robert F. Sidonio Jr
United States
12.55–13.00
Michael Laffan (Chair)
United Kingdom
12.15–12.25
Michael Laffan (Chair)
United Kingdom
12.25–12.55
Niamh O’Connell
Ireland
Robert F. Sidonio Jr
United States
12.55–13.00
Michael Laffan (Chair)
United Kingdom
This promotional Presentation Theatre is intended for healthcare professionals. Produced and paid for by Sobi™ and Sanofi.
Prescribing information for Alprolix® (eftrenonacog alfa) may vary depending on local approval in each country. Therefore, before prescribing, always refer to local materials such as the prescribing information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Swedish Orphan Biovitrum AB by email: drugsafety@sobi.com.